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ORIGINAL ARTICLE
Molecular Concordance Between Primary Breast Cancer
and Matched Metastases
Anne Bruun Krøigard, MD, PhD,*,† Martin Jakob Larsen, MSc, PhD,*,†
Mads Thomassen, MSc, PhD,*,† and Torben A. Kruse, MSc, PhD*,†
*Department of Clinical Genetics, Odense University Hospital, Odense C, Denmark; †Human
Genetics, Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark
n Abstract: Clinical management of breast cancer is increasingly personalized and based on molecular profiling. Often,
primary tumors are used as proxies for systemic disease at the time of recurrence. However, recent studies have revealed
substantial discordances between primary tumors and metastases, both with respect to traditional clinical treatment targets
and on the genomic and transcriptomic level. With the increasing use of molecularly targeted therapy, discordance of
actionable molecular targets between primary tumors and recurrences can result in nonoptimal treatment or unnecessary
side effects. The purpose of this review is to illuminate the extent of cancer genome evolution through disease progression
and the degree of molecular concordance between primary breast cancers and matched metastases. We present an over-
view of the most prominent studies investigating the expression of endocrine receptors, transcriptomics, and genome aber-
rations in primary tumors and metastases. In conclusion, biopsy of metastatic lesions at recurrence of breast cancer is
encouraged to provide optimal treatment of the disease. Furthermore, molecular profiling of metastatic tissue provides
invaluable mechanistic insight into the biology underlying metastatic progression and has the potential to identify novel,
potentially druggable, drivers of progression. n
Key Words: biopsy, breast cancer, cancer evolution, concordance, metastasis, targeted therapy
Breast cancer is the leading cause of cancer deathin women worldwide (1). In spite of extensive
treatment, about 30% of breast cancer patients will
experience spread of the malignant disease to distant
organs like liver, lungs, bone, and brain (2). The
metastatic process of breast cancer is highly complex
and to a large degree unexplored. Cancer cells are
characterized by genomic instability and are believed
to evolve in accordance with Darwinian positive selec-
tion and therefore further genetic evolution through-
out progression might be expected (3). The term
oncogene addiction (4) describes the cancer cell depen-
dence of particular driver genes for the maintenance
of the malignant phenotype and provides the rationale
for targeted therapy. However, the distinction between
driver and passenger mutations is dynamic due to the
shifting demands and challenges of a cancer cell, and
a shift in oncogenic drivers can develop during pro-
gression (5). Genomic and transcriptomic discordances
between primary tumors and metastases have the
potential to reveal novel drivers of metastatic progres-
sion and, thus, biopsies of metastatic tissue are impor-
tant for driving cancer research forward.
From the clinical perspective, the question of
genetic disparity between a primary tumor and its
recurrences becomes highly relevant not only to con-
firm the malignant diagnosis and preclude nonbreast
malignancy but also due to the use of molecularly tar-
geted therapy. Optimal management of cancer presup-
poses knowledge of actionable molecular targets in
the malignant cells and therefore potential genomic
discordance between primary tumors and recurrences
poses a clinical challenge. Thus, genomic, transcrip-
tomic, and proteomic concordance between primary
tumors and metastases are highly relevant from both
an academic and a clinical perspective.
Due to the extreme complexity of cancer biology,
the complete overview of all genetic, epigenetic, tran-
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scriptomic, and proteomic manifestations is very diffi-
cult to manage within one single study. Different tech-
nical approaches at each layer of biology result in a
varying degree of detail and each study typically
uncovers only a fraction of the complete picture.
The aim of this study was to provide an overview
of the research field of concordance between primary
breast tumors and matched metastases. The current
review is not exhaustive of all published studies in the
field, but presents a selection of the most prominent
work. Comprehensive literature searches were con-
ducted in PubMed with combinations of the following
search terms “breast cancer”, “breast carcinoma”,
“biopsy”, “metastasis”, “metastases”, “recurrence”,
“concordance”, “discordance”, “ER, HER2”, “gene
expression profiling” “CGH”, “aCGH”, “next genera-
tion sequencing”, and “epigenetics”. Only studies
comparing matched primary tumors and metastases
were considered. Studies were screened by titles and
abstracts and evaluated according to relevance, scien-
tific method, and impact in the research field.
ENDOCRINE RECEPTORS
From a clinical point of view, focused investiga-
tions of targetable molecular markers are highly rele-
vant. Tables 1 and 2 display selections of studies
evaluating concordance of estrogen receptor (ER),
progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2), respectively,
between paired primary tumors and metastases. The
studies quite consistently show surprisingly high dis-
cordance rates. It has been debated whether receptor
discordance is due to technical issues such as poor
reproducibility of the immunohistochemical technique,
inter- or intraobserver variance, or reflect a true bio-
logical phenomenon. Obviously, correct tissue han-
dling and fixation is crucial and the current
recommendations for clinical testing should be met
(6,7), however, analytical errors cannot account for
all of the discordances. Aurilio et al. performed a
meta-analysis of 48 articles evaluating ER, PR, and
HER2 receptor discordance between primary breast
cancer and metastases (8). The meta-analysis included
4200 patients evaluating ER status and found pooled
proportions of tumors shifting from positive to nega-
tive and negative to positive ER status of 24% and
14%, respectively. For PR status the same figures were
46% and 15%, and for HER2 status 13% and 5%,
and these data were based on a total of 2,739 and
2,987 patients, respectively. This clearly signals that a
loss of receptor is more frequent than gain of receptor,
confirming a biological phenomenon.
Most of the studied asynchronous metastases have
been subject to adjuvant treatment, which may
explain the high discordance rates. Cancer cell popula-
tions evolve dynamically and may be molded by the
selective pressures provided by treatment. Stratifica-
tion of patients allows insight into the phenomenon.
Lindstr€om et al. reported that the proportion of
patients loosing ER was highest in the group of
patients treated with endocrine therapy alone or in
combination with chemotherapy, lower in the group
treated with chemotherapy alone, and lowest in the
Table 1. Selection of Studies Analyzing Discordance of ER and PR Receptors Between Primary Tumors
and Matched Metastases
Author (ref) Year Method No. patients Analyzed metastatic site
Intervening treatment
between primary
tumor and metastases
Gain of
ER, %
Loss of
ER, %
Gain of
PR, %
Loss of
PR, %
Simmons et al. (51) 2009 IHC 25 Asynchronous metastases Yes, in some patients 0 12 0 28
Amir et al.* (52) 2012 IHC 117 Asynchronous metastases Yes, in some patients 16 15 8 74
Lindstr€om et al.* (9) 2012 IHC 459/430 Asynchronous metastases Yes, in some patients 7 24 7 33
Jensen et al. (53) 2012 IHC 118 Asynchronous metastases Yes, in some patients 3 8 – –
Heitz et al. (54) 2013 IHC 411 Asynchronous metastases Yes, in some patients 19 22 16 41
Curtit et al. (55) 2013 IHC 235 Asynchronous metastases Yes, in some patients 5 12 7 22
Aurilio et al. (56) 2013 IHC 107 Asynchronous metastases Yes, in some patients 3 18 3 40
Ibrahim et al. (57) 2013 IHC 120 Asynchronous metastases Not specified 7 9 8 33
Aurilio et al. (8) 2013 MA 4,200/2,739 Asynchronous metastases Yes, in some patients 14 24 15 46
Hoefnagel et al. (15) 2013 IHC 55 Several asynchronous
metastases
Not specified – – – –
Yang et al. (12) 2014 IHC 133 Asynchronous metastases Yes, in some patients 3 15 6 27
Qu et al. (58) 2014 IHC 48 Asynchronous metastases Yes, in some patients 4 10 2 14
*Included in the meta-analysis by Aurilio et al.
IHC, immune histochemistry; MA, meta-analysis.
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group of patients who received no treatment
(p < 0.01) (9). A similar effect for HER2 expression
was reported by Nakamura et al. showing that the
negative conversion rate of HER2 expression in meta-
static lesions was 37% in patients treated with trastu-
zumab and only 6% in patients not treated with
trastuzumab (p < 0.05) (10). This illustrates how
receptor positive cancers develop therapy-resistant
metastases due to positive selection of receptor nega-
tive cancer cells. That receptor discordance is highly
influenced by selective pressures of treatment is sup-
ported by the low number of discordant cases in a
study by Leni et al. comparing primary tumors and
synchronous metastases, i.e., without intervening
treatment (11).
Recently, Yang et al. found that among 105
patients ER discordance and HER2 discordance
between primary tumors and distant metastases
resulted in a worse overall survival and postrecurrence
survival (p < 0.05) compared with concordant cases
(12). Concordantly, Niikura et al., in a study includ-
ing only patients with HER2-positive primary tumors,
found that patients with discordance of HER2 status
had shorter overall survival than did patients with
concordant HER2 status (p = 0.003) (13). Lindstr€om
et al. reported that women with ER-positive primary
tumors that changed to ER-negative tumors had a sig-
nificant 48% increased risk of death compared with
women with stable ER-positive tumors (9). This intu-
itively makes sense, as tumors that are able to evade
targeted treatment by altering the expression of recep-
tors are more difficult to eradicate.
Conclusively, changes in ER and HER2 receptor
expression seem to be a frequent phenomenon in breast
cancer progression correlating with worse prognosis
and, thus, having both prognostic and clinical implica-
tions. American guidelines recommend HER2 receptor
status to be reevaluated at recurrence by biopsy at the
metastatic site (7). The European Society for Medical
Oncology (ESMO) second international consensus
guideline for advanced breast cancer (Nov. 2013) states
that a biopsy of a metastatic lesion should be per-
Table 2. Selection of Studies Analyzing Discordance of the HER2 Receptor Between Primary Tumors
and Matched Metastases
Author (Ref) Year Method
No.
patients Analyzed metastatic site
Intervening treatment between primary tumor
and metastases
Gain of
HER2, %
Loss of
HER2, %
Leni et al. (11) 2014 IHC, FISH 148 Synchronous ALN
metastases
No 2 3
Simmons
et al. (51)
2009 FISH 25 Asynchronous metastases 2% of patients received trastuzumab 8 0
Amir et al.* (52) 2012 IHC, FISH 117 Asynchronous metastases 4% of patients received trastuzumab 8 20
Lindstr€om
et al.* (9)
2012 IHC, FISH 104 Asynchronous metastases Not specified 5 8
Jensen et al. (53) 2012 IHC, FISH,
CISH
114 Asynchronous metastases One patient received adjuvant trastuzumab.
The two patients that lost HER2 positivity
had not received trastuzumab
7 2
Chan et al. (59) 2012 SISH, FISH 116 Asynchronous metastases 8% of patients had received adjuvant
trastuzumab, including the patient who was
HER2 discordant
0% 1%
Niikura et al. (13) 2012 IHC, FISH 182 Asynchronous metastases 41% of patients had received adjuvant
trastuzumab
– 24
Nakamura
et al. (10)
2013 IHC, FISH 156 Asynchronous metastases Adjuvant trastuzumab/no treatment 5 3
Heitz et al. (54) 2013 IHC, FISH 411 Asynchronous metastases 3% of patients had received adjuvant
trastuzumab
11 40
Curtit et al. (55) 2013 IHC, FISH 235 Asynchronous metastases 3% of patients had received adjuvant
trastuzumab
1 3
Aurilio et al. (56) 2013 IHC, FISH 86 Asynchronous metastases One patient received adjuvant trastuzumab 4 2
Ibrahim et al. (57) 2013 IHC, FISH 120 Asynchronous metastases None of the patients had received adjuvant
trastuzumab
12 5
Aurilio et al. (8) 2013 MA 2,987 Asynchronous metastases Not specified 5 13
Hoefnagel
et al. (15)
2013 IHC, SISH 55 Several asynchronous
metastases
Not specified – –
Yang et al. (12) 2014 IHC, FISH 133 Asynchronous metastases 9% of patients received trastuzumab 3 3
Qu et al. (58) 2014 IHC 48 Asynchronous metastases Not specified 4 4
*Included in the meta-analysis by Aurilio et al.
IHC, immune histochemistry; CISH, chromogenic in situ hybridization; FISH, fluorescence in situ hybridization; SISH, silver in situ hybridization; MA, meta-analysis.
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formed, if clinically feasible, to reassess biomarkers
(especially ER and HER2) at least once in the meta-
static setting (14). Addressing the issue of discordance
between primary tumors and metastases, it is recom-
mended at the level of an expert opinion, to consider
use of targeted therapy when receptors are positive in
at least one biopsy, regardless of timing (14).
It is, however, important to stress that biopsies
from different metastatic sites may be discordant. A
study by Hoefnagel et al. reports significant discor-
dance in ER status and PR status across different
metastases within the same patient (15). Thus, a single
metastatic site may not be representative of all dissem-
inated cancer cells and therefore, e.g., loss of ER
expression in a single metastatic biopsy does not nec-
essarily indicate that the patient will no longer benefit
from anti-estrogen treatment. Expression of the ER
receptor is in many cases epigenetically, thus reversi-
bly regulated and influenced by anti-estrogen treat-
ment and therefore re-expression of the receptor is
possible if endocrine treatment is discontinued. The
effect of changing the treatment according to biopsy
results at recurrence needs to be evaluated in large
patient cohorts.
GENE EXPRESSION PROFILING
Few studies have performed gene expression profil-
ing of primary breast cancers and matched axillary
lymph node metastases (16–19) as seen in Table 3.
Most studies have found gene expression patterns
of primary tumors and matched lymph node metas-
tases to be strikingly similar. Despite the high similar-
ity, some studies conclude that breast cancer
metastases are molecularly distinct from their primary
tumors, and genes differentially expressed between
primary tumors and metastases are reported. How-
ever, a very small overlap exists between the lists of
genes reported to be associated with the metastasis
phenotype between each study.
Very few studies have performed the comparison
using asynchronous distant metastatic tissue. Weigelt
et al. compared pairs of primary tumors and matched
distant metastases and reported highly similar gene
expression patterns (20), a metastasis-specific gene
expression profile was not found, and the study con-
cluded that metastatic capabilities were an inherent
feature of the primary tumor.
The contradictory results might reflect the short-
comings of gene expression assays to resolve the puz-
zle. Breast cancer is an extremely heterogeneous
disease and displays both intertumor heterogeneity
and intratumor heterogeneity. The pattern of somatic
mutations and copy number alterations as well as epi-
genetic modifications is highly unique to each cancer
genome and, thus, the transcriptional differences
between two breast cancer patients, even within the
same subtype, may be greater than the transcriptional
differences arising through progression of the disease
and therefore remain elusive in many gene expression
studies. Moreover, gene expression profiling does not
allow identification of subpopulations within the can-
cer tissue and report the mixed picture of transcrip-
tomes of cancer cells and stromal cells. Hao et al.
show that the expression at the transcript level does
not always correspond to expression at the protein
level (17), thus emphasizing the caution to be taken
when conclusions are drawn from gene expression
studies.
Woditschka et al. performed gene expression profil-
ing of matched primary tumors and brain metastases
and found two genes to be differentially expressed
(21). Studies of this nature address the issue of organ-
otropism, the phenomenon of special affinity of cancer
cells to particular organs, and have the potential to
reveal novel drivers of metastatic progression.
NONCODING RNA AND EPIGENETICS
Gene expression regulation by noncoding RNAs
and epigenetic mechanisms are likely to play key roles
in the metastatic process as the identified metastasis
suppressor genes are known to be transcriptionally
downregulated, rather than being hit by inactivating
mutations (22). Very few studies have explored differ-
ences in the expression of noncoding RNAs (23,24)
and epigenetic mechanisms including methylation pat-
terns (25–28) or histone acetylation comparing pri-
mary tumors and metastases. Differences in the
expression levels of miRNAs between matched pri-
mary tumors and metastases have been found (23)
and also long noncoding RNAs like HOTAIR have
been shown to be differentially expressed (24).
HOTAIR promotes metastasis by inducing chromatin
conformational changes and methylation changes lead-
ing to gene expression patterns favorable for metasta-
sis. Thus, the effect of increased transcription of a
single long noncoding RNA can influence the expres-
sion of many genes and thereby set an entirely altered
cell state. Also, DNA methylome changes during can-
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cer progression are still highly unexplored, but likely
contribute massively to the metastatic phenotype. A
recent study profiling the DNA methylome of 44
matched primary tumors and regional metastases was
able to identify a metastasis-specific methylation signa-
ture (25).
TARGETED GENOMIC APPROACHES
Different targeted approaches have been employed
to address the issue of genomic concordance between
primary tumors and metastases, as seen in Table 4.
Moelans et al. investigated the copy number concor-
dance between 55 primary tumors and corresponding
distant metastases of 21 established oncogenes and
tumor suppressor genes using multiplex ligation-depen-
dent probe amplification (29). The study found overall
no significant difference in copy numbers, concluding
that there was overall little genomic progression from
primary breast tumors to their distant metastases. Con-
versely, other targeted studies have reported discor-
dances. A targeted study based on Snapshot genotyping
of 100 primary tumors and paired recurrences evaluat-
ing concordance of PIK3CA mutations found a net gain
mutation rate in metastatic disease (30) as 21 patients
changed genotype from wild type to mutant, compared
with 11 patients who lost the mutation allele in the
metastasis. Moreover, laser capture microdissection
revealed microheterogeneity for the PIK3CA mutation
in primary tumors, confirming subclonality among can-
cer cells. A recent study including 73 patients with
matched primary tumors and asynchronous metastases
identified five pairs with PIK3CA mutation in meta-
static tissue but not primary tumor and two patients
with mutation in primary tumor but not in the meta-
static sample (31).
Using targeted next-generation sequencing (NGS),
Meric-Bernstam et al. investigated the concordance of
Table 3. Selection of Studies Based on Gene Expression Profiling and DNA Methylation Profiling
Author (Ref) Year Method No. patients Analyzed metastatic site Result
Weigelt et al. (20) 2003 GEP 8 Asynchronous distant metastases Highly similar gene expression profiles of
primary tumors and metastases
Hao et al. (17) 2004 GEP, TMA 9 Synchronous ALN metastases Some genes differentially expressed between
primary tumors and metastases
Suzuki and Tarin (18) 2007 GEP 10 Synchronous ALN metastases Very similar gene expression profiles. A small
number of genes were differentially
expressed between primary tumors and
metastases
Vecchi et al. (19) 2008 TMA 26 Synchronous ALN metastases Some genes differentially expressed between
primary tumors and metastases
Ellsworth et al. (16) 2008 GEP 20 Synchronous ALN metastases 51 differentially expressed genes
Feng et al. (27) 2010 MP 38 Synchronous ALN metastases Investigation of six putative tumor suppressor
genes suggests that hypermethylation of
tumor suppressor genes is extended from
primary tumors to metastases
Barekati et al. (28) 2012 MP 24 Synchronous ALN metastases Investigation of 12 breast cancer candidate
genes reveals methylation heterogeneity
between primary tumors and metastases
Gravgaard et al. (23) 2012 miRNA microarray 14 ALN metastases, distant metastases 15 miRNAs were differentially expressed
between primary tumors and corresponding
distant metastases
Chisholm et al. (24) 2012 lncRNA in situ
hybridization
54 Unspecified metastases The lncRNAs HOTAIR and EZH2 had
increased expression in metastases
compared with matched primary tumors
Woditschka et al. (21) 2014 GEP of 502
cancer-related
genes
23 Brain metastases Two genes, BARD and RAD51, were
overexpressed in brain metastases
compared with both matched primary tumors
and compared with unlinked systemic
metastases
Reyngold et al. (25) 2014 MP, GEP 44 Regional metastases Integrated analysis of methylation and gene
expression identified genes whose
expression correlated with metastasis-
specific methylation
Moarii et al. (26) 2014 MP 48 Synchronous ALN metastases,
local recurrences, contralateral
breast carcinomas
Methylation patterns can help to distinguish
local recurrences from new primary tumors
GEP, gene expression profiling; TMA, tissue microarray analysis; ALN, axillary lymph node; LncRNA, long noncoding RNA; MP, methylation profiling.
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182 cancer-related genes in 33 paired primary tumors
and recurrences (32). The study found that 86.6% of
the somatic mutations and 62.3% of the copy number
aberrations were concordant between primary tumors
and recurrences and that actionable molecular targets
to be lost or gained in the metastases compared with
matched primary tumors.
GLOBAL GENOMIC APPROACHES
A number of studies have applied comparative
genomic hybridization (CGH) to detect copy number
discordances between primary breast tumors and
matched metastases, as seen in Table 5, with rather
contradictory results. Some studies found a signifi-
cantly higher number of aberrations in metastases
compared with primary tumors (33,34), whereas
others did not (35–38). Using CGH, Torres et al.
found extensive clonal divergence between primary
tumors and metastases and higher frequency of alter-
ations in primary breast cancers with metastases com-
pared with tumors with no metastatic spread (38).
This finding is also reported by Desouki et al. using
array CGH (39). Conversely, also using array CGH,
Poplawski et al. found 20% higher number of aberra-
tions in primary tumors compared with metastases
(40). This result is quite surprising as the general
assumption is that additional genetic aberrations can
accumulate through cancer progression due to the
inherent genomic instability underlying cancer. One
explanation might be the heterogeneity within the pri-
mary tumor, where several subclones with adverse
aberrations coexist, whereas metastases are seeded
from one of these subclones and therefore contains
Table 4. Selection of Studies Comparing Primary Tumors and Metastatic Lesions Using Targeted
Genomic Approaches
Author (Ref) Year Method
No.
patients Analyzed metastatic site Target Result
Jensen et al. (30) 2011 TMA,
SNaPshot gt,
IHC
100 Asynchronous metastases PIK3CA, PTEN, pAKT,
Ki67, ER, HER2
PIK3CA mutation in 45% of primary
tumors and 53% of metastases,
showing a net gain in PIK3CA
mutations. PTEN deficiency
dropped from 26% in primary
tumors to 20% in the metastases
Moelans et al. (29) 2014 MLPA 55 Asynchronous metastases 21 cancer-related genes Overall no significant difference in
mean MLPA copy numbers
between primary tumors and
metastases
Meric-Bernstam
et al. (32)
2014 NGS 33 Asynchronous metastases 182 cancer-related genes 86.6% of the 112 somatic mutations
detected were concordant. 62.3%
of the 159 CNAs detected were
concordant
Schleifman
et al. (31)
2014 IHC, SNP gt 73 Asynchronous metastases PIK3CA, AKT1, PTEN, Ki67. Five pairs had PIK3CA mutation in
metastatic tissue but not primary
tumor and two pairs had PIK3CA
mutation in the primary tumor but
not in the metastatic sample
Deng et al. (47) 2014 Sanger s 17 CTCs, DTCs, and metastases PIK3CA Mutational discordance between
CTCs, DTCs, and metastases,
and among CTCs isolated at
different time points
Rothe et al. (48) 2014 NGS 17 Metastases, cfDNA in plasma 50 cancer-related genes In some cases, analysis of cfDNA in
plasma seemed more
representative of the mutational
spectrum of the metastatic disease
than a single biopsy of a metastatic
lesion
De Mattos
Arruda et al. (49)
2014 NGS 1 Synchronous bone and liver
metastases, cfDNA in plasma
300 cancer-related genes A longitudinal monitoring of the
patient with liquid biopsies the
mutant allele fractions identified
in the cfDNA varied over time and
mirrored the pharmacodynamic
response
TMA, tissue microarrays; IHC, immune histochemistry; ALN, axillary lymph node; CNA, copy number aberration; CTCs, circulating tumor cells; DTCs, disseminated tumor cells; MLPA,
multiplex ligation probe amplification; NGS, next-generation sequencing; Gt, genotyping; Ds, direct sequencing; S, sequencing.
Molecular Concordance Between Primary Breast Cancer and Matched Metastases • 425
only a subset of aberrations. Another explanation may
be a higher degree of normal cell admixture within
the metastases, resulting in lower sensitivity. The
inconclusiveness of the studies is likely due to the rela-
tively poor resolution of the CGH technique which
renders this assay obsolete compared with copy num-
ber analysis using NGS, or arrayCGH/SNP-array tech-
nology.
Using whole-genome sequencing, Shah et al.
sequenced a distant metastasis, biopsied from a pleu-
ral effusion, of one breast cancer patient with ER-
positive, HER2-negative lobular breast cancer, and
found 32 somatic nonsynonymous coding mutations
(41). Five of the mutations were present in the corre-
sponding primary tumor, 6 mutations were present
subclonally in the primary tumor, 19 were not
detected in the primary tumor, and 2 were undeter-
mined. The study confirms molecular heterogeneity
within the primary tumor and substantial further
genomic evolution of the metastasis. The patient had
been treated with adjuvant anti-estrogen therapies, but
received no neo-adjuvant or adjuvant chemotherapy.
A mediating factor for the genomic discordance
between primary tumor and recurrence may be the
great time span of 9 years between the primary tumor
and the recurrence in addition to the selective pres-
sures provided by anti-estrogen therapies.
A study by Ding et al. based on a single breast can-
cer patient performed whole-genome sequencing of a
basal-like (ER negative, PR negative, and HER2 nega-
tive) primary breast cancer, a brain metastasis, a
xenograft, and matched peripheral blood (42). The
Table 5. Selection of Studies Comparing Primary Tumors and Metastatic Lesions Using Global Geno-
mic Approaches
Author (Ref) Year Method
No.
patients Analyzed metastatic site Result
Nishizaki et al. (34) 1997 CGH 16 Local recurrences,
ALN metastases, or
distant metastases
The total number of aberrations detected exclusively in the lymph node
metastases or distant metastases was higher than that for the primary
tumors (2.5 versus 0.7 p < 0.05)
Kuukasj€arvi et al. (35) 1997 CGH 29 Asynchronous metastases Mean number of changes detected by CGH was 8.7 (range 0–20) in primary
tumors and 9.0 (range 1–24) in metastases––no significant difference.
Pairwise clonality analysis of matched primary tumors and metastases
revealed that 69% of the metastases were highly similar to their primary
tumor and 31% of the metastases were genetically different from their
primary tumor
Torres et al. (38) 2007 CGH 12 ALN metastases No significant difference in the number of genomic imbalances between
primary tumors and metastases. Clustering analysis showed extensive
clonal divergence between primary tumors and metastases. Higher
frequency of alterations in breast cancers with metastases than in tumors
without metastases
Friedrich et al. (33) 2008 CGH 40 Local recurrences,
ALN metastases,
systemic metastases
Significant higher number of chromosomal imbalances in local recurrences
(22.6 versus 16.2 p = 0.02), ALN metastases (21.5 versus 18.0 p = 0.03)
and systemic metastases (28.1 versus 22.4 p = 0.02) compared with
primary tumors
Li et al. (36) 2008 CGH 29 ALN metastases 26 of 29 pairs clustered together in unsupervised hierarchical clustering
Santos et al. (37) 2008 CGH 20 SLN metastases No significant difference in copy number aberrations between primary
tumors and SLN
Shah et al. (41) 2009 NGS 1 Asynchronous distant
metastasis
Of 32 coding, nonsynonymous mutations detected in the distant metastasis,
5 mutations were present in the primary tumor, 6 mutations were
subclonally present in the primary tumor, 19 mutations were not detected
in the primary tumor, and 2 were undetermined
Poplawski et al. (40) 2010 aCGH 13 Synchronous ALN
metastases
20% higher number of aberrations in primary tumors (mean 33) compared
with metastases (mean 27)
Desouki et al. (39) 2010 aCGH 30 Synchronous ALN
metastases
Higher frequency of copy number alterations in breast cancers with
metastases than in tumors without metastases. Similar number of copy
number alterations in primary tumors and ALN metastases
Ding et al. (42) 2010 NGS 1 Asynchronous distant
metastasis and xenograft
Two de novo mutations and a large deletion exclusively found in the distant
metastasis, 20 shared mutations at higher frequency in the distant
metastasis
Krøigard et al. (43) 2015 NGS 1 Asynchronous distant
metastasis
In the distant metastasis, 17 additional nonsynonymous point mutations
were found. The distant metastasis retained all previous copy number
aberrations and displayed 18 copy number loss and 18 copy number gain
events in addition to the early acquired copy number events
CGH, comparative genomic hybridization; aCGH, array comparative genomic hybridization; ALN, axillary lymph node; SLN, sentinel lymph node; CSFTC, cerebrospinal fluid-derived
tumor cells; DTCs, disseminated tumor cells; NGS, next-generation sequencing.
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patient had been treated with neo-adjuvant
chemotherapy. The time interval from the primary
surgery till appearance of the brain metastasis was
8 months and in this time span the patient received
radiation therapy. The xenograft tumor line was gen-
erated from a sample of the primary tumor biopsied
before treatment. Of the 50 validated point mutations
and small indels detected, 48 were present in all three
tumors. The metastasis contained two de novo muta-
tions and a large deletion not present in the primary
tumor and significant enrichment of 20 shared muta-
tions. The two de novo mutations private to the
metastasis were not likely to be essential to the meta-
static process, as one of them was a silent mutation
and both mutations were absent in the xenograft,
which nevertheless displayed full metastatic abilities.
Hence, the metastasis-enabling mutations were most
likely to be present already within the genome of the
primary tumor. The study found that 96.11% and
93.98% of copy number aberrations found in the pri-
mary tumor were retained in the metastasis and the
xenograft, respectively, indicating that most primary
tumor copy number aberrations are preserved during
disease progression. The quite high percentages imply
that very few copy number events are evolved in the
primary tumor after dissemination, rendering them
private to the primary tumor. This suggests that dis-
semination of the successful metastatic cell most likely
occurred relatively late in molecular time from the
most advanced clone of the primary tumor. Con-
versely, only 80.65% of metastasis and 61.29% of
xenograft copy number aberrations were found in the
primary tumor, revealing substantial additional devel-
opment of copy number events after dissemination
from the primary tumor. Thus, copy number aberra-
tions constitute the largest degree of genomic discor-
dance between the primary tumor and the metastasis
in this study. All five detected translocations were con-
cordant between primary tumor and metastasis. The
relatively small genomic discordance between the pri-
mary tumor and metastasis in this study may be
explained by the relatively short time span of
8 months between the primary tumor and metastasis.
A recent study reports the genome evolution of one
breast cancer patient with ER-positive, HER2-negative
invasive ductal carcinoma including two pre-invasive
regions, a primary tumor, and a distant metastasis
located in a contralateral periclavicular lymph node,
representing recurrence after 4 years (43). The patient
had been treated with neo-adjuvant and adjuvant
chemotherapy and adjuvant anti-estrogen therapy.
This study similarly found the metastasis to be seeded
from the most advanced clone in the primary tumor,
thus relatively late in molecular time. The study
revealed substantial mutational discordance between
the primary tumor and metastasis with 17 additional
somatic nonsynonymous point mutations and 36 addi-
tional copy number aberrations in the metastasis,
whereas early acquired copy number aberrations were
kept as imprints in the genome. The genomic evolu-
tion presented in this study may be strongly influenced
by the selective pressures provided by the adjuvant
treatment.
Studies with broad or global approaches detecting
discordances between primary tumors and metastases
may provide novel insight into genes or pathways
playing a role in the metastatic process.
LIQUID BIOPSY
An appealing alternative for biopsy of metastatic
lesions is the minimally invasive “liquid biopsy” with
molecular characterization of circulating tumor cells
(CTCs) (44) or tumor cell derived cell-free DNA
(cfDNA) in plasma (45). Circulating tumor DNA
levels are found to correlate with tumor burden (46)
and may be used to monitor treatment response,
detect subclinical residual disease, and for directing
therapy decisions.
These methods actually address the heterogeneity
of breast cancer as the CTCs and cfDNA in plasma
originates from all malignant lesions within the
patient. This is supported in recent studies comparing
primary tumors, metastases, and CTCs or cfDNA
(47–49). However, the methods are dependent on the
detection of cancer-specific genetic changes and rely
on the assumption that the cancer genomes does not
evolve to an extent where it loses identifiable markers.
Another concern is that the cell-free DNA originates
from apoptotic cancer cells, i.e., the cancer cells suc-
cumbing to therapy, whereas the viable subset of can-
cer cells may be more difficult to detect (50), thus
demanding a high sensitivity of the assay.
CONCLUSION
The increasing use of molecularly targeted therapy
in breast cancer treatment emphasizes the importance
of establishing whether primary tumors may be used as
surrogates of disseminated disease. Discordance of
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actionable molecular targets has great clinical implica-
tions for optimal patient care and the avoidance of
unnecessary side effects. Naturally, influencing factors
of genomic, transcriptomic, and proteomic discordance
between primary tumors and metastases include selec-
tive forces provided by treatment, the degree of geno-
mic instability of the cancer genome, and the time span
in which genomic alterations can take place. Explana-
tions of the inconsistencies of the reported studies
include methodological issues, relatively low numbers
of studied patients, and maybe most importantly the
heterogeneity of breast cancer. Due to clonal hetero-
geneity a small section of a primary tumor might not
be representative of the entire clonality of the tumor,
leaving small subclones undetected, and the selective
pressures provided by treatment can entail positive
selection of initially overlooked cancer cell populations.
Moreover, it is likely that the different subtypes of
breast cancer may be more or less prone to further
genomic, transcriptomic, and proteomic evolution.
Overall, the studies reveal substantial discordances
between primary tumors and metastases, which stres-
ses the need for analysis of metastatic tissue at recur-
rences. International guidelines state that a biopsy of a
metastatic lesion should be performed, if clinically fea-
sible. It should, however, be kept in mind that evi-
dence of the clinical impact of changes in treatment
based on biopsy of metastases have yet to be evalu-
ated and that one biopsy may not be representative of
all disseminated cancer cells.
In addition to the direct clinical advantages of
biopsy of recurrences, the molecular characterization
of metastatic lesions and the molecular differences
between matched primary tumors and metastatic
lesions have the potential to reveal novel, potentially
targetable, drivers of metastatic progression. The
extreme complexity of cancer biology necessitates
analysis not only on a single level, as the novel targets
for molecularly targeted therapy can be revealed at
the DNA, RNA, protein level, or epigenetically. Liq-
uid biopsies with analysis of CTCs or tumor-derived
cfDNA are likely to play an increasing role in cancer
patient monitoring and have the advantage of address-
ing the issue of genetic heterogeneity.
FUNDING
Odense University Hospital Free Research Fund,
Harboefonden, Aase og Ejnar Danielsen Fond, Fabri-
kant Einar Willumsens Mindelegat, Grosserer M.
Brogaard og Hustrus Mindefond, Kong Christian Den
Tiendes Fond, Dagmar Marshalls Fond, Axel Muus-
feldts Fond, Kræftfonden, Raimond og Dagmar
Ringgard-Bohns Fond, Grete og Sigurd Pedersens
Fond, Syddansk Universitets Forskningsfond, Poul og
Ellen Hertz’ Fond, Fonden til Lægevidenskabens
Fremme, Grosserer A.V. Lykfeldt og Hustrus Legat,
Familien Hede Nielsens Fond, Lykfeldts Legat, Dansk
Kræftforskningsfond, Ulla og Mogens Folmer Ander-
sens Fond, Ingeniør K. A. Rohde og Hustrus Legat,
Krista og Viggo Petersens Fond, Danish Strategic
Research Council, DBCG-TIBCAT.
CONFLICT OF INTEREST
The authors declare that they have no competing
interests.
REFERENCES
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal
A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–
108.
2. Redig AJ, McAllister SS. Breast cancer as a systemic disease:
a view of metastasis. J Intern Med 2013;274:113–26.
3. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of
cancer genes and mutational processes in breast cancer. Nature
2012;486:400–4.
4. Weinstein IB. Cancer. Addiction to oncogenes–the Achilles
heal of cancer. Science 2002;297:63–4.
5. Polyak K. Heterogeneity in breast cancer. J Clin Invest
2011;121:3786–8.
6. Hammond MEH, Hayes DF, Dowsett M, et al. American
Society of Clinical Oncology/College of American Pathologists
guideline recommendations for immunohistochemical testing of
estrogen and progesterone receptors in breast cancer (unabridged
version). Arch Pathol Lab Med 2010;134:e48–72.
7. Wolff AC, Hammond MEH, Hicks DG, et al. Recommenda-
tions for human epidermal growth factor receptor 2 testing in breast
cancer. Arch Pathol Lab Med 2014;138:241–56.
8. Aurilio G, Disalvatore D, Pruneri G, et al. A meta-analysis of
oestrogen receptor, progesterone receptor and human epidermal
growth factor receptor 2 discordance between primary breast cancer
and metastases. Eur J Cancer 2014;50:277–89.
9. Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically
used breast cancer markers such as estrogen receptor, proges-
terone receptor, and human epidermal growth factor receptor 2
are unstable throughout tumor progression. J Clin Oncol
2012;30:2601–8.
10. Nakamura R, Yamamoto N, Onai Y, Watanabe Y, Kawana
H, Miyazaki M. Importance of confirming HER2 overexpression of
recurrence lesion in breast cancer patients. Breast Cancer
2013;20:336–41.
11. Ieni A, Barresi V, Caltabiano R, et al. Discordance rate of
HER2 status in primary breast carcinomas versus synchronous axil-
lary lymph node metastases: a multicenter retrospective investiga-
tion. Onco Targets Ther 2014;7:1267–72.
12. Yang Y-F, Liao Y-Y, Yang M, Peng N-F, Xie S-R, Xie Y-F.
Discordances in ER, PR and HER2 receptors between primary and
428 • krøigard et al.
recurrent/metastatic lesions and their impact on survival in breast
cancer patients. Med Oncol 2014;31:214.
13. Niikura N, Liu J, Hayashi N, et al. Loss of human epider-
mal growth factor receptor 2 (HER2) expression in metastatic sites
of HER2-overexpressing primary breast tumors. J Clin Oncol
2012;30:593–9.
14. Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd inter-
national consensus guidelines for advanced breast cancer (ABC2).
Breast 2014;23:489–502.
15. Hoefnagel LDC, van der Groep P, van de Vijver MJ, et al.
Discordance in ERa, PR and HER2 receptor status across different
distant breast cancer metastases within the same patient. Ann Oncol
2013;24:3017–23.
16. Ellsworth RE, Seebach J, Field LA, et al. A gene expression
signature that defines breast cancer metastases. Clin Exp Metastasis
2009;26:205–13.
17. Hao X, Sun B, Hu L, et al. Differential gene and protein
expression in primary breast malignancies and their lymph node
metastases as revealed by combined cDNA microarray and tissue
microarray analysis. Cancer 2004;100:1110–22.
18. Suzuki M, Tarin D. Gene expression profiling of human
lymph node metastases and matched primary breast carcinomas:
clinical implications. Mol Oncol 2007;1:172–80.
19. Vecchi M, Confalonieri S, Nuciforo P, et al. Breast cancer
metastases are molecularly distinct from their primary tumors.
Oncogene 2008;27:2148–58.
20. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL,
Van’t Veer LJ. Gene expression profiles of primary breast tumors
maintained in distant metastases. Proc Natl Acad Sci USA
2003;100:15901–5.
21. Woditschka S, Evans L, Duchnowska R, et al. DNA double-
strand break repair genes and oxidative damage in brain metastasis of
breast cancer. J Natl Cancer Inst 2014;106:doi: 10.1093/jnci/dju145.
22. Hurst DR, Welch DR. Metastasis suppressor genes at the
interface between the environment and tumor cell growth. Int Rev
Cell Mol Biol 2011;286:107–80.
23. Gravgaard KH, Lyng MB, Laenkholm A-V, et al. The
miRNA-200 family and miRNA-9 exhibit differential expression in
primary versus corresponding metastatic tissue in breast cancer.
Breast Cancer Res Treat 2012;134:207–17.
24. Chisholm KM, Wan Y, Li R, Montgomery KD, Chang HY,
West RB. Detection of long non-coding RNA in archival tissue: cor-
relation with polycomb protein expression in primary and metastatic
breast carcinoma. PLoS ONE 2012;7:e47998.
25. Reyngold M, Turcan S, Giri D, et al. Remodeling of the
methylation landscape in breast cancer metastasis. PLoS ONE
2014;9:e103896.
26. Moarii M, Pinheiro A, Sigal-Zafrani B, et al. Epigenomic
alterations in breast carcinoma from primary tumor to locoregional
recurrences. PLoS ONE 2014;9:e103986.
27. Feng W, Orlandi R, Zhao N, et al. Tumor suppressor genes
are frequently methylated in lymph node metastases of breast can-
cers. BMC Cancer 2010;10:378.
28. Barekati Z, Radpour R, Lu Q, et al. Methylation signature
of lymph node metastases in breast cancer patients. BMC Cancer
2012;12:244.
29. Moelans CB, van der Groep P, Hoefnagel LDC, et al. Geno-
mic evolution from primary breast carcinoma to distant metastasis:
Few copy number changes of breast cancer related genes. Cancer
Lett 2014;344:138–46.
30. Jensen JD, Laenkholm A-V, Knoop A, et al. PIK3CA muta-
tions may be discordant between primary and corresponding meta-
static disease in breast cancer. Clin Cancer Res 2011;17:667–77.
31. Schleifman EB, Desai R, Spoerke JM, et al. Targeted bio-
marker profiling of matched primary and metastatic estrogen recep-
tor positive breast cancers. PLoS ONE 2014;9:e88401.
32. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, et al.
Concordance of genomic alterations between primary and recurrent
breast cancer. Mol Cancer Ther 2014;13:1382–9.
33. Friedrich K, Weber T, Scheithauer J, et al. Chromosomal
genotype in breast cancer progression: comparison of primary and
secondary manifestations. Cell Oncol 2008;30:39–50.
34. Nishizaki T, DeVries S, Chew K, et al. Genetic alterations
in primary breast cancers and their metastases: direct comparison
using modified comparative genomic hybridization. Genes Chromo-
som 1997;19:267–72.
35. Kuukasj€arvi T, Karhu R, Tanner M, et al. Genetic hetero-
geneity and clonal evolution underlying development of asyn-
chronous metastasis in human breast cancer. Cancer Res
1997;57:1597–604.
36. Li J, Gromov P, Gromova I, et al. Omics-based profiling of
carcinoma of the breast and matched regional lymph node metasta-
sis. Proteomics 2008;8:5038–52.
37. Santos SCL, Cavalli IJ, Ribeiro EM, et al. Patterns of DNA
copy number changes in sentinel lymph node breast cancer metas-
tases. Cytogenet Genome Res 2008;122:16–21.
38. Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, Teix-
eira MR. Intratumor genomic heterogeneity in breast cancer with
clonal divergence between primary carcinomas and lymph node
metastases. Breast Cancer Res Treat 2007;102:143–55.
39. Desouki MM, Liao S, Huang H, et al. Identification of
metastasis-associated breast cancer genes using a high-resolution
whole genome profiling approach. J Cancer Res Clin Oncol
2011;137:795–809.
40. Poplawski AB, Jankowski M, Erickson SW, et al. Frequent
genetic differences between matched primary and metastatic breast
cancer provide an approach to identification of biomarkers for dis-
ease progression. Eur J Hum Genet 2010;18:560–8.
41. Shah SP, Morin RD, Khattra J, et al. Mutational evolution
in a lobular breast tumour profiled at single nucleotide resolution.
Nature 2009;461:809–13.
42. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a
basal-like breast cancer metastasis and xenograft. Nature
2010;464:999–1005.
43. Krøigard AB, Larsen MJ, Lænkholm A-V, et al. Clonal
expansion and linear genome evolution through breast cancer pro-
gression from pre-invasive stages to asynchronous metastasis. Onco-
target 2015;6:5634–49.
44. Polzer B, Medoro G, Pasch S, et al. Molecular profiling of
single circulating tumor cells with diagnostic intention. EMBO Mol
Med 2014;6:1371–86.
45. Schwarzenbach H. Circulating nucleic acids as biomarkers
in breast cancer. Breast Cancer Res 2013;15:211.
46. Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of cir-
culating tumor DNA to monitor metastatic breast cancer. N Engl J
Med 2013;368:1199–209.
47. Deng G, Krishnakumar S, Powell AA, et al. Single cell muta-
tional analysis of PIK3CA in circulating tumor cells and metastases
in breast cancer reveals heterogeneity, discordance, and mutation
persistence in cultured disseminated tumor cells from bone marrow.
BMC Cancer 2014;14:456.
48. Rothe F, Laes J-F, Lambrechts D, et al. Plasma circulating
tumor DNA as an alternative to metastatic biopsies for mutational
analysis in breast cancer. Ann Oncol 2014;25:1959–65.
49. De Mattos-Arruda L, Weigelt B, Cortes J, et al. Capturing
intra-tumor genetic heterogeneity by de novo mutation profiling of
Molecular Concordance Between Primary Breast Cancer and Matched Metastases • 429
circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol
2014;25:1729–35.
50. Castle J, Shaker H, Morris K, Tugwood JD, Kirwan CC.
The significance of circulating tumour cells in breast cancer: a
review. Breast 2014;23:552–60.
51. Simmons C, Miller N, Geddie W, et al. Does confirmatory
tumor biopsy alter the management of breast cancer patients with
distant metastases? Ann Oncol 2009;20:1499–504.
52. Amir E, Miller N, Geddie W, et al. Prospective study evalu-
ating the impact of tissue confirmation of metastatic disease in
patients with breast cancer. J Clin Oncol 2012;30:587–92.
53. Jensen JD, Knoop A, Ewertz M, Laenkholm AV. ER, HER2,
and TOP2A expression in primary tumor, synchronous axillary
nodes, and asynchronous metastases in breast cancer. Breast Cancer
Res Treat 2012;132:511–21.
54. Heitz F, Barinoff J, du Bois O, et al. Differences in the
receptor status between primary and recurrent breast cancer - the
frequency of and the reasons for discordance. Oncology
2013;84:319–25.
55. Curtit E, Nerich V, Mansi L, et al. Discordances in estrogen
receptor status, progesterone receptor status, and HER2 status
between primary breast cancer and metastasis. Oncologist
2013;18:667–74.
56. Aurilio G, Monfardini L, Rizzo S, et al. Discordant hor-
mone receptor and human epidermal growth factor receptor 2 status
in bone metastases compared to primary breast cancer. Acta Oncol
Stockh Swed 2013;52:1649–56.
57. Ibrahim T, Farolfi A, Scarpi E, et al. Hormonal receptor,
human epidermal growth factor receptor-2, and Ki67 discordance
between primary breast cancer and paired metastases: clinical
impact. Oncology 2013;84:150–7.
58. Qu Q, Zong Y, Fei X, et al. The importance of biopsy in
clinically diagnosed metastatic lesions in patients with breast cancer.
World J Surg Oncol 2014;12:93.
59. Chan A, Morey A, Brown B, Hastrich D, Willsher P, Ingram
D. A retrospective study investigating the rate of HER2 discordance
between primary breast carcinoma and locoregional or metastatic
disease. BMC Cancer 2012;12:555.
430 • krøigard et al.
